Going Beyond the Pill

Brain disease currently affects more than 700 million people globally, representing 13% of the global disease burden¹.

We work tirelessly to restoring brain health because:

• More than 70% of people living with brain disease experience discrimination²
• People living with brain disease live between 10-20 years less than healthy individuals³
• The World Health Organisation (WHO) estimates that the global economy loses about 1 trillion USD a year in productivity due to depression and anxiety alone⁴.

Our commitment is to empower patients to give them the tools and resources they need to understand their disease and its unfolding.

Our commitment is to continuously challenge status quo and push our science further to make real differences for patients.

Our commitment is to families to bring evidence-based data, visibility and support to their work in managing a chronic disease.

Our commitment is to communities to end the stigma, fear, and silence that surrounds brain diseases.

We call this Progress in Mind.

Research and development (R&D) of new and improved treatments is at the core of what we do. We have state-of-the-art research centers in Denmark and California, US, and more than 800 employees work in our R&D units. We fund independent research and collaborate closely with strategic partners all over the world. We provide free of charge, non-commercial and evidence-based medical education and training for healthcare professionals on neurology and psychiatry via the Lundbeck Institute seminars, publications and online campus, and through our Progress in Mind Resource Centre.  

Despite some improvements, discrimination against people with brain diseases continues to be a serious and pervasive social problem. Stigma operates on many levels from the personal to the professional. To this end, we take our position as specialists seriously and use our voice to raise awareness, challenge standards and increase opportunities for patients to participate more fully in their communities and networks. Despite some improvements, discrimination against people with brain diseases continues to be a serious and pervasive social problem. Stigma operates on many levels from the personal to the professional. 

We do this by actively sponsoring and participating in disease awareness, anti-stigma, and mental health promotion campaigns, working with the international advocacy community. 

Being diagnosed with a brain disease brings complex experiences. We aim to amplify patients’ voices and needs through our publications, events, engagement activities and partnerships with advocacy groups and patient organizations – together we carry the message further than any one single group can do alone.

To leverage the support of families, loved ones and carers, we work with caregivers and advocacy groups to support evidence generation and awareness campaigns on the value they bring to disease management.

For more than 70 years, we’ve been pushing the boundaries of neuroscience. Even though research into the brain costs more, takes longer and fails at a higher rate than most other medical research, we have not abandoned the psychiatric and neurological space. Indeed, with brain diseases sharply on the increase, it’s more important than ever that we accelerate our efforts. As one of the only global pharmaceutical companies to focus exclusively on brain diseases, we have demonstrated staying power, our specialist knowledge, and a comprehensive treatment approach.

Convinced that we can help improve the quality of life for people affected by brain disease and ever-mindful of this purpose, Lundbeck perseveres.